Ozempic for Weight Loss: Who Qualifies and Medical Considerations

Last reviewed: May 29, 2026

Last updated: May 29, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

No, not everyone can get Ozempic for weight loss. FDA approval requires specific criteria: a BMI of 30 or higher, or BMI of 27+ with weight-related health conditions such as type 2 diabetes, hypertension, or heart disease. Medical history, current medications, and individual metabolic factors all influence eligibility and safety.

Understanding whether GLP-1 therapy is right for you requires more than checking a BMI box. This decision involves evaluating your metabolic health, genetic predispositions in peptide pathways, and individual risk factors. PlexusDx helps patients navigate this conversation with providers using precision-wellness insights tailored to their unique health profile.

Medical Eligibility Criteria for GLP-1 Weight Loss Therapy

GLP-1 receptor agonist medications like semaglutide (Ozempic, Wegovy) require documented medical need. The FDA approves these for chronic weight management in adults with BMI 30+ or BMI 27+ plus a weight-related comorbidity. Type 2 diabetes status, cardiovascular disease history, and metabolic syndrome also factor into prescriber decisions.

Beyond BMI and diagnoses, providers assess medication interactions, kidney function, and thyroid history. Gastrointestinal disorders, personal or family history of medullary thyroid cancer, and Multiple Endocrine Neoplasia syndrome are contraindications. A qualified provider conducts thorough medical screening to ensure safety and appropriateness for each individual.

Metabolic and Genetic Factors Influencing GLP-1 Response

Not all patients respond identically to GLP-1 therapy. Genetic variants in GLP1R, GIPR, FTO, and MC4R genes influence appetite regulation, satiety signaling, and metabolic rate. Understanding your genetic predispositions in these peptide pathways may help provide context for personalized treatment planning and expected response patterns.

Genetic Factor	Relevance to GLP-1 Response
GLP1R rs6923761	Influences GLP-1 receptor sensitivity and baseline appetite control
GIPR rs1800437	Affects glucose-dependent insulinotropic peptide signaling and weight response
FTO rs9939609	Associated with appetite regulation and metabolic rate variation
MC4R rs17782313	Impacts melanocortin pathway and satiety signaling mechanisms

Evaluating Your Individual Health Profile Before Starting Treatment

A comprehensive pre-treatment assessment should examine your fasting glucose, lipid panel, blood pressure, and kidney function. These biomarkers establish a baseline for monitoring treatment effects and identifying potential complications early. Documenting weight-loss history, previous medication trials, and lifestyle factors provides context for realistic goal-setting.

Your healthcare provider should discuss side-effect tolerance, injection comfort if using injectables, and commitment to lifestyle modifications. GLP-1 medications work best with consistent nutrition and activity habits. This conversation ensures informed consent and appropriate expectations about onset, efficacy timeline, and long-term sustainability.

Who Should Not Use GLP-1 Therapy and Safety Boundaries

Absolute contraindications include personal or family history of medullary thyroid carcinoma, MEN 2 syndrome, severe pancreatitis, diabetic retinopathy requiring urgent treatment, and acute kidney injury. Pregnancy, breastfeeding, and unstable psychiatric or eating disorder history also warrant caution. Providers must carefully weigh risks and benefits in patients with severe gastrointestinal disease or recent abdominal surgery.

Common side effects—nausea, vomiting, constipation, and decreased appetite—are dose-dependent and often temporary. Serious but rare adverse events include pancreatitis, gallbladder complications, and dehydration-related kidney issues. Regular provider follow-up, dose titration, and clear communication about new symptoms are essential safeguards for anyone considering this therapy.

How PlexusDx Supports a More Personalized Approach

PlexusDx's Precision Peptide Genetic Test may help provide context for your individual suitability for GLP-1 therapy. By analyzing genetic variants in GLP1R, GIPR, FTO, and MC4R pathways, this test reveals predispositions that influence appetite signaling and metabolic response. This information should be interpreted with a qualified healthcare provider as one piece of a comprehensive eligibility assessment.

The genetic test does not predict exact medication response or guarantee weight-loss outcomes. Instead, it identifies your genetic predispositions in peptide regulatory pathways, which can support a more informed conversation about whether GLP-1 therapy aligns with your metabolic profile. This insight complements traditional clinical evaluation, not replaces it.

If you're exploring GLP-1 options and meet basic medical criteria, PlexusDx offers compounded semaglutide ($179–$229/month) and compounded tirzepatide ($229–$309/month) from licensed 503A pharmacies. Combined with genetic testing ($99 add-on or $298 standalone) and provider guidance, you gain a personalized roadmap for safe, effective weight-management therapy.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Oral starts at $229-$509/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.